

Attorney Docket No. 5776.204-US


Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

CLAIM LISTING

1. (Currently amended) A method for ~~treating a condition related to~~
angiogenesis reducing angiogenesis or neovascularization, said method
 comprising administering to a patient in need of such ~~treatment~~ method an effective
 amount of a compound having the general formula Ia



wherein R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, C_{1-6} -alkyl, C_{1-6} -alkoxy, hydroxy, NR^7R^8 , cyano, methylthio or $-SO_2NR^7R^8$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and

Y is $\underline{>N-CH_2-}$, $\underline{>CH-CH_2-}$ or $\underline{>C=CH-}$ wherein only the underscored atom participates in the ring system; or

Y is $\underline{-CH_2N(-)CH_2-}$, $\underline{-CH_2N(-)CH_2-}$, $\underline{-(C=O)N(-)CH_2-}$, $\underline{-CH_2N(-)(C=O)-}$, $\underline{-CH_2CH(-)CH_2-}$, $\underline{CH_2CH(-)CH_2-}$, $\underline{-CH_2C(-)=CH-}$, $\underline{-CH=C(-)CH_2-}$, $\underline{-OCH(-)CH_2-}$, $\underline{-CH_2CH(-)O-}$, $\underline{-SCH(-)CH_2-}$, $\underline{-CH_2CH(-)S-}$, wherein only the underscored atom participates in the ring system; or

Y is $\underline{>N-}$, $\underline{>CH-}$, $\underline{>N-(C=O)-}$ or $\underline{>C=C(R^8)-}$, wherein only the underscored atom participates in the ring system and R^8 is hydrogen or C_{1-6} -alkyl; or

Y is $\underline{>CH-O-}$ or $\underline{>CH-S(O)_y}$ wherein y is 0, 1 or 2, or $\underline{-N(R^8)-}$ wherein R^8 is hydrogen or C_{1-6} -alkyl, and wherein only the underscored atom participates in the ring system; and

X is completion of an optional bond, ortho-phenylene, $-O-$, $-S-$, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2-CH=CH-$, $-CH_2-(C=O)-$, $-(C=O)-CH_2-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^8)-(C=O)-$, $-(C=O)-N(R^8)-$, $-O-CH_2-$, $-CH_2-O-$, $-OCH_2O-$, $-CH_2OCH_2-$, $-S-CH_2-$, $-CH_2-S-$, $-(CH_2)N(R^8)-$, $-N(R^8)(CH_2)-$, $-N(CH_3)SO_2-$, $-SO_2N(CH_3)-$, $-CH(R^9)CH_2-$, $-CH_2CH(R^9)-$, $-(C=O)-$

sh to enter
 AC 9/19/04

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001


Via facsimile to: 571-273-0571

, -N(R⁸)- or -(S=O)- wherein R⁷ and R⁸ independently are hydrogen or C₁₋₆-alkyl; and wherein R⁹ is C₁₋₆-alkyl or phenyl; and

p and q independently are 0 or 1; and

r is 0, 1, 2, 3 or 4; and


Z is selected from



wherein R⁶ is OH or C₁₋₆-alkoxy; and

... is optionally a single bond or a double bond; or

Z is selected from



wherein n is 1 or 2;

Attorney Docket No. 5776,204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

R^3 is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

R^4 is $-OH$, $-NH_2$, $-NHOH$ or C_{1-6} -alkoxy; and


R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{10} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{11} is hydrogen or C_{1-6} -alkyl; and

... is optionally a single bond or a double bond; or

Z is selected from



wherein u is 0 or 1;

R^3 is $-(CH_2)_mOH$ or $-(CH_2)_sCOR^4$ wherein m is 0, 1, 2, 3, 4, 5 or 6 and s is 0 or 1 and wherein

R^4 is $-OH$, $-NH_2$, $-NHOH$ or C_{1-6} -alkoxy; and

R^5 is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

R^{10a} is hydrogen or C_{1-6} -alkyl; and

A is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene; or


Z is selected from

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571




wherein M_1 and M_2 independently are C or N; and

R^{35} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and

R^{33} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and


R^{34} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_wCOR^{31}$, $-(CH_2)_wOH$ or $-(CH_2)_wSO_2R^{31}$ wherein R^{31} is hydroxy, C_{1-6} -alkoxy or NHR^{32} , wherein R^{32} is hydrogen or C_{1-6} -alkyl, and w is 0, 1 or 2; or

R^{34} is selected from



; or

Z is



wherein b is 0, 1, 2, 3 or 4; and

Attorney Docket No. 5776.204-US


Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

B is $-\text{CH}=\text{CR}^{49}-$, $-\text{CR}^{49}=\text{CH}-$, $-\text{C}\equiv\text{C}-$, $-(\text{C}=\text{O})-$, $-(\text{C}=\text{CH}_2)-$, $-(\text{CR}^{49}\text{R}^{40})-$, $-\text{CH}(\text{OR}^{41})-$, $-\text{CH}(\text{NHR}^{41})-$, phenylene, C_{3-7} -cycloalkylene or the completion of a bond, wherein R^{49} and R^{40} independently are hydrogen, C_{1-6} -unbranched alkyl, C_{3-6} -branched alkyl or C_{3-7} -cycloalkyl and wherein R^{41} is hydrogen or C_{1-6} -alkyl; and

U is



wherein R^{42} is hydrogen, $-(\text{CH}_2)_c\text{OH}$ or $-(\text{CH}_2)_d\text{COR}^{47}$ wherein c is 0, 1, 2, 3, 4, 5 or 6 and d is 0 or 1 and wherein R^{47} is $-\text{OH}$, $-\text{NHR}^{44}$ or C_{1-6} -alkoxy wherein R^{44} is hydrogen or C_{1-6} -alkyl; and

R^{43} is cyano, $-\text{NR}^{45}\text{R}^{47}$, $-\text{NR}^{45}-\text{V}$ or $-(\text{CHR}^{48})_e-\text{V}$ wherein R^{45} and R^{47} independently are hydrogen or C_{1-6} -alkyl and wherein e is 0, 1, 2, 3, 4, 5 or 6 and wherein R^{48} is hydrogen, halogen, cyano, trifluoromethyl, hydroxy, C_{1-6} -alkyl, C_{1-6} -alkoxy, $-\text{NR}^{45}\text{R}^{47}$ or $-\text{COOH}$, and wherein V is C_{3-8} -cycloalkyl, aryl or heteroaryl, which rings may optionally be substituted with one or more halogen, cyano, trifluoromethyl, hydroxy, methylthio, C_{1-6} -alkyl or C_{1-6} -alkoxy; or


U is selected from

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571



wherein g is 0, 1 or 2; and

R^{11u} is hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or phenyl optionally substituted with halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and



R^{12u} is $-(CH_2)_hOH$ or $-(CH_2)_jCOR^{17u}$ wherein h is 0, 1, 2, 3, 4, 5 or 6 and j is 0 or 1 and wherein R^{17u} is $-OH$, $-NHR^{20u}$ or C_{1-6} -alkoxy wherein R^{20u} is hydrogen or C_{1-6} -alkyl; and R^{13u} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

Attorney Docket No. 5776.204-US


Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

 R^{14u} is hydrogen or C_{1-6} -alkyl; and C is C_{1-6} -alkylene, C_{2-4} -alkenylene or C_{2-6} -alkynylene; and --- is optionally a single bond or a double bond; and R^{18u} is selected fromwherein M_1 and M_2 independently are C or N; and R^{19u} is hydrogen, C_{1-6} -alkyl, phenyl or benzyl; and R^{15u} is hydrogen, halogen, trifluoromethyl, nitro or cyano; and R^{16u} is hydrogen, halogen, trifluoromethyl, nitro, cyano, $-(CH_2)_kCOR^{17u}$, $-(CH_2)_kOH$ or $-(CH_2)_kSO_2R^{17u}$ wherein k is 0, 1 or 2; or R^{16u} is selected from

; or

 Z is selected from

Attorney Docket No. 5776.204-US


Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571

wherein R^{53} is $-(CH_2)_{pp}COOH$ wherein pp is 2, 3, 4, 5 or 6; or

Z is




wherein tt and t independently are 0, 1 or 2; and

R^{63} is H, C_{1-6} -alkyl or optionally substituted benzyl;

R^{64} and R^{65} independently are H, C_{1-8} -alkyl, C_{3-7} -cycloalkyl, phenyl, thienyl, benzyl, or R^{64} and R^{65} together with the C-atom they are attached to form a 3 - 8 membered carbocyclic ring; and

R^{66} is H or C_{1-6} -alkyl; or

Z is selected from



wherein D is $-CH_2-$, $-O-$, $-S-$ or $-N(R^7)-$ wherein R^7 is hydrogen or C_{1-6} -alkyl; and

R^{3m} is $-(CH_2)_{mm}OH$ or $-(CH_2)_{mp}COR^4$ wherein mm and mp are 1, 2, 3 or 4 and R^4 is OH, NH_2 , $NHOH$ or C_{1-6} -alkoxy; or


having the general formula Ib

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571



(Ib)


wherein R^{1b} and R^{2b} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C₁₋₆-alkyl or C₁₋₆-alkoxy; and

R^{3b} is hydrogen or C₁₋₃-alkyl; and

Ab is C₁₋₃-alkylene; and

Yb is >CH-CH₂-, >C=CH-, >CH-O-, >C=N-, >N-CH₂- wherein only the underscored atom participates in the ring system; and

Zb is selected from




Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571



wherein nb is 1 or 2; and

 R^{11b} is hydrogen or C_{1-6} -alkyl; and R^{12b} is hydrogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or phenyl optionally substituted with halogen, trifluoro-methyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and R^{13b} is hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and R^{14b} is $-(CH_2)_{mb}OH$ or $-(CH_2)_{mb}COR^{15b}$ wherein mb is 0, 1, 2, 3, 4, 5 or 6 and tb is 0 or 1 and wherein R^{15b} is -OH, NH_2 , -NHOH or C_{1-6} -alkoxy; and R^{16b} is C_{1-6} -alkyl or $-B_b-COR^{15b}$, wherein B_b is C_{1-6} -alkylene, C_{2-6} -alkenylene or C_{2-6} -alkynylene and R^{15b} is the same as above; and

... is optionally a single bond or a double bond; or


having the general formula Ic

Attorney Docket No. 5776.204-US

Hansen et al.

Serial No. 09/872,127 Filed June 1, 2001

Via facsimile to: 571-273-0571



(Ic)


wherein R^{1c} and R^{2c} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy;

X_c is ortho-phenylene, -O-, -S-, $-C(R^{6c}R^{7c})$ -, $-CH_2CH_2$ -, $-CH=CH-CH_2$ -, $-CH_2-CH=CH$ -, $-CH_2-(C=O)$ -, $-(C=O)-CH_2$ -, $-CH_2CH_2CH_2$ -, $-CH=CH$ -, $-N(R^{8c})-(C=O)$ -, $-(C=O)-N(R^{8c})$ -, $-O-CH_2$ -, $-CH_2-O$ -, $-OCH_2O$ -, $-S-CH_2$ -, $-CH_2-S$ -, $-(CH_2)N(R^{8c})$ -, $-N(R^{8c})(CH_2)$ -, $-N(CH_3)SO_2$ -, $-SO_2N(CH_3)$ -, $-CH(R^{10c})CH_2$ -, $-CH_2CH(R^{10c})$ -, $-(C=O)$ -, $-N(R^{9c})$ - or $-(S=O)$ - wherein R^{6c} , R^{7c} , R^{8c} and R^{9c} independently are hydrogen or C_{1-6} -alkyl, and wherein R^{10c} is C_{1-6} -alkyl or phenyl; Y_c is C or N;

... is optionally a single bond or a double bond, and ... is a single bond when Y_c is N;

mc is 1, 2, 3, 4, 5 or 6; and


Z_c is $-COOR^{3c}$ or



wherein R^{3c} is H or C_{1-6} -alkyl; or

having the general formula Id

Attorney Docket No. 5776.204-US
 Hansen et al.
 Serial No. 09/872,127 Filed June 1, 2001
 Via facsimile to: 571-273-0571



(Id)

wherein R^{1d} and R^{2d} independently are hydrogen, halogen, trifluoromethyl, hydroxy, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

X_d is -O-, -S- or -S(=O)-; and

rd is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and

Z_d is selected from



wherein R^{3d} is $-(CH_2)_{md}OH$ or $-(CH_2)_{pd}COR^{4d}$ wherein md and pd independently are 0, 1, 2, 3 or 4 and R^{4d} is OH, NH_2 , $NHOH$ or C_{1-6} -alkoxy; or
 a pharmaceutically acceptable salt of any of the foregoing.

2. (Currently amended) The method according to claim 1 wherein the angiogenesis or neovascularization condition is related to reduction is for treatment of cancer.
3. (Currently amended) The method according to claim 1 wherein the angiogenesis or neovascularization is ocular condition is related to ocular neovascularization.
4. (Original) The method according to claim 1 wherein, in formula Ia,

Attorney Docket No. 5776.204-US
 Hansen et al.
 Serial No. 09/872,127 Filed June 1, 2001
 Via facsimile to: 571-273-0571

R^1 , R^{1a} , R^2 and R^{2a} independently are hydrogen, halogen, trifluoromethyl, C_{1-6} -alkyl or C_{1-6} -alkoxy; and

Y is $>\underline{N}-CH_2-$, $>\underline{CH}-CH_2-$ or $>\underline{C}=CH-$ wherein only the underscored atom participates in the ring system; and

X is $-O-$, $-S-$, $-C(R^7R^8)-$, $-CH_2CH_2-$, $-CH=CH-CH_2-$, $-CH_2CH=CH-$, $-CH_2CH_2CH_2-$, $-CH=CH-$, $-N(R^7)(C=O)-$, $-O-CH_2-$, $-(C=O)-$ or $-(S=O)-$ wherein R^7 and R^8 independently are hydrogen or C_{1-6} -alkyl; and

p and q are 0, and

r is 1, 2 or 3; and

Z is selected from



wherein R^6 is OH or C_{1-6} -alkoxy; and

..... is optionally a single bond or a double bond; and

a pharmaceutically acceptable salt of any of the foregoing.

5. (Original) The method according to claim 4 wherein the compound is selected from the group consisting of:

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

Attorney Docket No. 5776.204-US
Hansen et al.
Serial No. 09/872,127 Filed June 1, 2001
Via facsimile to: 571-273-0571

(R)-1-(3-(Fluoren-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(Thioxanthen-9-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenz[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(4-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-butyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)ethyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10H-Phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10H-Phenoxazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(S)-1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-pyrrolidinacetic acid;

(R)-1-(3-(3-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(2-Trifluoromethyl-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(5-Oxo-10H-phenothiazin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(11H-10-Oxa-5-aza-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

Attorney Docket No. 5776.204-US
Hansen et al.
Serial No. 09/872,127 Filed June 1, 2001
Via facsimile to: 571-273-0571

1-(3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic acid;

(R)-1-(3-(6,7-Dihydro-5H-dibenzo[b,g]azocin-12-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-Methoxy-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(10-Methyl-11-oxo-10,11-dihydro-5H-dibenzo[b,e][1,4]diazepin-5-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(3-(9(H)-Oxo-10H-acridin-10-yl)-1-propyl)-3-piperidinecarboxylic acid;

(R)-1-(2-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(2-(6,11-Dihydrodibenz[b,e]oxepin-11-ylidene)-1-ethyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Chloro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Bromo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Fluoro-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

Attorney Docket No. 5776.204-US
Hansen et al.
Serial No. 09/872,127 Filed June 1, 2001
Via facsimile to: 571-273-0571

(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(Z)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(E)-(R)-1-(3-(2-Iodo-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride;

(R)-1-(3-(2-Methoxy-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidinecarboxylic acid hydrochloride,

and a pharmaceutically acceptable salt of any of the foregoing.

6. (Cancelled)
7. (Cancelled)
8. (Cancelled)
9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Cancelled)
13. (Cancelled)
14. (Cancelled)
15. (Cancelled)
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Cancelled)
22. (Cancelled)
23. (Cancelled)
24. (Cancelled)
25. (Cancelled)
26. (Cancelled)
27. (Cancelled)
28. (Cancelled)
29. (Cancelled)
30. (Cancelled)
31. (Cancelled)
32. (Cancelled)

Attorney Docket No. 5776.204-US
Hansen et al.
Serial No. 09/872,127 Filed June 1, 2001
Via facsimile to: 571-273-0571

33. (Cancelled)

34. (Currently amended) The method according to claim 1 wherein the ~~pharmaceutical composition~~ pharmaceutically acceptable salt is in a form suitable for oral administration.

Attorney Docket No. 5776.204-IJS
Hansen et al.
Serial No. 09/872,127 Filed June 1, 2001
Via facsimile to: 571-273-0571

RESPONSE

The Examiner states in the Office Action Summary that claims numbered 1-34 are pending in the application, claims 6-33 are withdrawn from consideration, claims numbered 1, 2, 4, 5 and 34 are rejected, and claim number 3 is objected to.

(1) The Examiner has rejected claim number 1, 2, 4, 5 and 34 under 35 U.S.C. §112, first paragraph, for failing to comply with the written description requirement. Specifically: the examiner states the specification, while being enabling for the specific cancer disclosed, does not reasonable provide enablement for the term "a condition related to angiogenesis" or "cancer".

Applicant has amended claims numbered 1, 2 and 3 to more clearly define the present invention. Applicant believes these amendments obviate the Examiner's rejection based on treatment of cancer and treatment of conditions related to angiogenesis.

Applicant respectfully requests reconsideration and withdrawal of the rejections under 35 U.S.C. §112, first paragraph.

(2) The Examiner has rejected claim number 1, 2, 4, 5 and 34 under 35 U.S.C. §103(a) as being unpatentable over the Jørgensen et al. WO 96/31497.

Applicant has amended claims numbered 1, 2 and 3 to more clearly define the present invention. Applicant believes these amendments obviate the Examiner's rejection based on treatment of cancer.

Applicant respectfully requests reconsideration and withdrawal of the rejections under 35 U.S.C. §103(a).

Applicant has amended claim 34 to correct antecedent basis.

In view of the above, Applicant respectfully submits all claims are in condition for allowance. *Applicant respectfully requests notification via an Advisory Action or telephone call if the Examiner deems the case is not in condition for allowance.*

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. Applicant respectfully requests that

Attorney Docket No. 3776.204-US
Hansen et al.
Serial No. 09/872,127 Filed June 1, 2001
Via facsimile to: 571-273-0571

a timely Notice of Allowance be issued in this case.

Respectfully submitted,

Date: September 15, 2004



Rosemarie R. Wilk-Orescan
Registration Number 45,220
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE